Tatiana KATCHO DJIKEUSSI

Dr. Tatiana KATCHO DJIKEUSSI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Pan African Medical Journal
Verified
Journal Article
Open access
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
RARogers Ajeh
Rogers Ajeh
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
PEPeter Ebasone
Peter Ebasone
PTPatrice Tchendjou
Patrice Tchendjou
ADAnastase Dzudie
Anastase Dzudie
Research is a vital component for the development of any country. In Cameroon, HIV Operational research is rapidly growing, however, it faces some intractable problems which can only be solved through an urgent, strategic, efficient, and collaborative approach involving key stakeholders. The Kribi meeting (09 and 10th December 2020) brought together under the auspices of the Ministry of Public Health leading HIV research organisations and connected HIV researchers and actors from different sectors. These actors disseminated and discussed recent research findings and worked out mechanisms to advance HIV research development, developed new ideas and identified priority research areas, with emphasis on translational research. The official launching and consolidation of Cam-HERO was a critical step and it is hoped that these synergistic efforts will catalyse attainment of the 95-95-95 goals in Cameroon.

21 January 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
Boris Tchakounte YounguiBoris Tchakounte Youngui
Boris Tchakounte Youngui
AMAlbert Mambo
Albert Mambo
GBGeorges Bonabe
Georges Bonabe
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
Introduction: SARS-CoV-2 contact tracing in Cameroon has been done manually using paper forms and phone calls. However, there were reports of inaccurate contact details, resulting in delays in identifying and testing contacts. A recently introduced digital contact-tracing module using the Mamal Pro app automatically sends SMS messages to notify all reported contacts and the district unit. We assessed the total costs, cost per contact reached, tested and found SARS-CoV-2-positive for both manual (standard of care, SOC) and app-based (intervention, ITV) contact-tracing approaches. Methods: A cluster randomised trial comparing the SOC and ITV was implemented across eight health districts in Cameroon between October 2022 and March 2023. The cost per contact reached, tested and found SARS-CoV-2-positive was calculated by dividing the total cost of each approach by the number of contacts reached, tested and found SARS-CoV-2-positive, respectively. We also estimated the minimum number of SARS-CoV-2-positive contacts that need to be found and the maximum total cost of ITV in order to equal the SOC’s cost per SARS-CoV-2-positive contact. Results: In the SOC, of 849 contacts identified, 463, 123 and 5 were reached, tested and found SARS-CoV-2-positive, respectively. In the ITV, of the 854 contacts identified, 801, 182 and 4 were reached, tested and found SARS-CoV-2-positive, respectively. In the SOC, the cost per contact reached was US$70, per contact tested was US$262 and per SARS-CoV-2-positive contact was US$6437. In the ITV, the cost per contact reached was US$48, per contact tested was US$210 and per SARS-CoV-2-positive contact was US$9573. The minimum number of SARS-CoV-2-positive contacts the ITV needs to find and the maximum total cost of the ITV to equal the SOC’s cost per SARS-CoV-2-positive were 6 and US$25 748, respectively. Conclusion: Using the Mamal Pro digital contact tracing app module increased the number of clients’ contacts reached and tested for SARS-CoV-2 and reduced the cost per contact reached and tested. Trial registration number: NCT05684887.

23 December 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
RMRose Otieno Masaba
Rose Otieno Masaba
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
JNJames Ndimbii
James Ndimbii
SMSushant Mukherjee
Sushant Mukherjee
Introduction: Understanding costs associated with identification of emerging infections is critical to inform the policy. Nested within a randomised controlled trial that found that a test-all (TA) model for rapid SARS-CoV-2 testing identified more SARS-CoV-2 cases than the standard screen-and-test (ST) model. Our study assessed the cost-effectiveness of integrating SARS-CoV-2 services into maternal, neonatal and child health (MNCH), HIV and tuberculosis (TB) clinics using the two models in Cameroon and Kenya. Methods: The total costs of implementing the TA and ST models in Cameroon and Kenya were estimated from a health systems perspective using a micro-costing method. The cost per client tested (CPCT) and tested positive (CPCTP) for SARS-CoV-2 were estimated by dividing the total cost of each model by the number of clients tested and tested positive, respectively. A decision tree and cost-effectiveness acceptability curve were used to compare the cost-effectiveness of the two models. Results: In Cameroon, the total cost of the TA model was US$141,942, while the ST model was US$48,020. In the TA model, the CPCT was US$7.66 and the CPCTP was US$508.75, whereas in the ST model, they were US$25.02 and US$727.58, respectively. In the TA model, the biggest cost was SARS-CoV-2 antigen rapid detection tests (Ag-RDTs) at 61% (US$86,853), whereas in the ST model, it was personnel at 39% (US$18,592). In Kenya, the total cost was US$39,264 in the TA model and US$27,500 in the ST model. The TA CPCT was US$13.04 and the CPCTP was US$1,189.81, whereas in the ST model the costs were $125.00 and $1,250.01 respectively. In both models in Kenya, the biggest expenditure was personnel, at 45% ($17,696) of cost in TA and 56% ($15,267) in ST. In both countries, the TA model was more cost-effective. Conclusions: Implementation of the TA model is a more cost-effective approach to increase early identification of individuals with SARS-CoV-2 infection.

23 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
VSVishwas B Sovani
Vishwas B Sovani
RKRogacien Kana
Rogacien Kana
GLGuedem Nekame Jinette Lorraine
Guedem Nekame Jinette Lorraine
ABAwelsa Benoit
Awelsa Benoit
YAYaoua Z. Aladji
Yaoua Z. Aladji
Snakebite envenomation (SBE) is a major public health issue in sub-Saharan Africa (SSA), particularly in Cameroon. This Phase IV, multicenter, open-label study was conducted from June 2024 to December 2024 to evaluate the safety and efficacy of PANAF-Premium™, a World Health Organization (WHO)-approved polyvalent antivenom that was introduced in Cameroon in 2023, given that prospectively gathered data and studies on this antivenom’s safety in SSA are limited. In total, 130 victims admitted to four district hospitals in North Cameroon with confirmed SBE were included. Data on envenomation syndromes, clinical outcomes, adverse events, and treatment response were recorded. Echis species were responsible for most bites, while clinical syndromes included hemotoxic (68.5%), cytotoxic (30.8%), and neurotoxic (0.8%) presentations. On average, victims required 3.34 vials and 5.55 days for clinical recovery. Early antivenom administration significantly reduced the number of antivenom vials required to manage the symptoms (p = 0.003) and hospital stay (p = 0.049). Seventeen patients experienced mild to moderate adverse events. Two deaths and a case of kidney injury were noted, all unrelated to antivenom use. These study findings indicate the safety and effectiveness of PANAF-Premium™ antivenom, meeting WHO performance targets. The results highlight the importance of timely antivenom administration in treating SBEs.

8 August 2024 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
NHNelia Hoffman
Nelia Hoffman
RMRose Masaba
Rose Masaba
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
JNJames Ndimbii
James Ndimbii
RMRhoderick Machekano
Rhoderick Machekano
Introduction: Early diagnosis of SARS-CoV-2 infection is key to preventing severe disease and poor outcomes in vulnerable populations, such as pregnant women and people living with HIV or diagnosed with tuberculosis (TB). We assessed outcomes achieved with the integration of SARS-CoV-2 antigen-detecting rapid diagnostic testing (Ag-RDT) into maternal, neonatal and child health (MNCH); HIV and TB clinics in the Catalysing COVID-19 Action project. Methods: Screening and testing for SARS-CoV-2 per national guidelines were integrated into MNCH, HIV and TB clinics in 50 health facilities in Cameroon and Kenya. In Cameroon, screening and testing were done by existing facility staff, while in Kenya, additional community workers and laboratory staff were involved. Clients aged >2 years attending MNCH, HIV and TB clinics between May and October 2022 were included in the study. We estimated the proportion of participants screened, tested and tested positive; calculated the SARS-CoV-2 case detection rate per 1000 attendees and determined factors associated with screening, testing and positivity. Results: Overall, 528 567 attendee visits were reported in Cameroon (282 404) and Kenya (246 163), with screening for SARS-CoV-2 performed in 256 049 (48.4%), showing substantive variations between countries (62.6% in Cameroon and 32.2% in Kenya). Among the 256 049 screened, 19 013 (7.4%) were eligible for testing (9.0% in Cameroon and 3.9% in Kenya), of whom 12 934 (68.0%) were tested for SARS-CoV-2 including 9866/15 934 (61.9%) in Cameroon and 3068/3079 (96.6%) in Kenya. A total of 390 (3.0%) positive tests were identified (329/9866, 3.3%, in Cameroon and 61/3068, 2.0%, in Kenya). Country integration strategy, facility level, setting and clinic were independently associated with screening and testing. Conclusions: Integration of SARS-CoV-2 Ag-RDT in MNCH, HIV and TB clinics in both countries allowed detection of SARS-CoV-2 cases among vulnerable populations. Integration strategies should consider facility settings and additional human resources in high-volume facilities to improve screening and testing proportions. Trial registration number: NCT05498727.

13 July 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
NBNilesh Bhatt
Nilesh Bhatt
RMRose Otieno Masaba
Rose Otieno Masaba
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
AYAida Yemaneberhan
Aida Yemaneberhan
LSLeonie Simo
Leonie Simo
RMRhoderick Machekano
Rhoderick Machekano
Introduction: Identifying SARS-CoV-2 infection in high-risk populations is critical. We examined SARS-CoV-2 case detection (CD) in ‘TA’ versus ‘screen-and-test’ models of rapid antigen testing integration in maternal neonatal and child health (MNCH), HIV and tuberculosis (TB) clinics in Cameroon (C) and Kenya (K). Methods: From May to October 2022, we conducted a cluster-randomised trial with 10 facilities per country randomised to the ‘test-all’ (TA) intervention arm or the standard ‘screen-and-test’ (ST) arm. Individuals aged >2 years attending HIV, TB and MNCH clinics were eligible for SARS-CoV-2 testing. The primary outcome was the SARS-CoV-2 CD, defined as the number of SARS-CoV-2 infections detected per 1 000 attendees in MNCH, HIV and TB clinics. We estimated the intervention arm-specific CDs by combining the facility-specific estimates using a weighted approach. Results: There were 80 828 attendee visits in the TA model (63 492 C, 17 336 K) and 71 254 in the ST model (56 589 C, 14 665 K). About 17.4% (K) and 29.0% (C) were tested under the TA model. The overall CD was 2.90 (95% CI:1.76 to 4.79) per 1 000 attendee visits in the TA model and 1.20 (95% CI:0.73 to 1.99) in the ST model (RR=2.41, 95% CI:1.18 to 4.91, p=0.018). The TA model had a significantly higher SARS-CoV-2 CD in MNCH clinics (2.91 vs 1.11, p=0.012), while CD estimates in HIV (2.88 vs 1.40, p=0.203) and TB (10.24 vs 4.57, p=0.051) clinics, although higher in TA model compared with ST model, were not statistically different. Conclusions: The TA model identified more SARS-CoV-2 cases than the screen-and-test model, even with low testing coverage. The TA model could be considered in future epidemics for early detection of SARS-CoV-2 infection among vulnerable populations, but effective implementation requires additional human resources to manage testing in high volume clinics. Trial registration number: NCT05382130.